XML 11 R4.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:    
Research and development $ 429,420 $ 740,325
General and administrative 927,394 510,445
Depreciation and amortization of intangible assets 23,531 24,101
Restructuring charges 0 0
Total operating expenses 1,380,345 1,274,871
Loss from operations (1,380,345) (1,274,871)
Other income (expense):    
Other income 9,054 34,541
Interest expense (11,566) (262,597)
Amortization of debt discount (13,468) (703)
Loss on forward purchase agreement (2,156,837) 0
Change in fair value of derivative liabilities 0 (325,085)
Loss on debt extinguishment 0 0
Total other income (expense) (2,172,817) (553,844)
Loss from continuing operations before provision for income taxes (3,553,162) (1,828,715)
Provision for income taxes 0 0
Loss from continuing operations (3,553,162) (1,828,715)
Loss from discontinued operations attributable to common shareholders (1,252,276) 0
Gain on sale of discontinued operations attributable to common shareholders 1,534,479  
Net loss (3,270,959) (1,828,715)
Dividends on Legacy Series A, Legacy Series C-1, and Legacy C-2 preferred stock 0 (311,168)
Net loss attributable to common stockholders $ (3,270,959) $ (2,139,883)
Basic    
Net loss from continuing operations - basic $ (0.16) $ (1.91)
Discontinued operations, net of tax - basic 0.02 0
Net loss per common share - basic (0.14) (1.91)
Diluted    
Net loss from continuing operations - diluted (0.16) (1.91)
Discontinued operations, net of tax - diluted 0.02 0
Net loss per common share - diluted $ (0.14) $ (1.91)
Weighted average of shares outstanding , Basic 22,915,160 1,122,529
Weighted average of shares outstanding , Diluted 22,915,160 1,122,529